600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Closed 04-18 15:00:00
48.00
-0.78
-1.60%
| High48.92 | Low47.86 | Vol25.33M |
| Open48.58 | D1 Closing48.78 | Amplitude2.17% |
| Mkt Cap306.19B | Tradable Cap306.19B | Total Shares6.38B |
| T/O1.22B | T/O Rate0.40% | Tradable Shares6.38B |
| P/B6.73 | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Hengrui Medicine Gets Nod to Trial Anti-Tumor Drug; Shares Up 3%
MT Newswires Live · 04-14
Hengrui Medicine Gets Registration Certificate for Abrocitinib Sulfate Tablets
MT Newswires Live · 04-10
Hengrui Medicine Obtains Drug Registration for Ankylosing Spondylitis Treatment
MT Newswires Live · 04-09
Hengrui Medicine Grants Merck Licensing Rights to Fertility Drug
MT Newswires Live · 04-08
BRIEF-Jiangsu Hengrui Signs Licensing Agreement With Merck
Reuters · 04-07
Jiangsu Hengrui Pharmaceuticals Says Signed Licensing Agreement for Shr7280 Project With Merck KGaA
THOMSON REUTERS · 04-07
Jiangsu Hengrui Medicine Gets China Approval for Cancer Drug Trials
MT Newswires Live · 04-04
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 80 Yuan From 60 Yuan, Keeps at Buy
MT Newswires Live · 04-03
BRIEF-Mycovia Pharmaceuticals Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'S Recognition For The Inclusion Of Vivjoa® (Oteseconazole) Capsules In The Chinese National Reimbursement Drug List
Reuters · 04-02
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusion of Vivjoa® (Oteseconazole) Capsules in the Chinese National Reimbursement Drug List
THOMSON REUTERS · 04-02
Hengrui Medicine's Unit Gets Nod to Trial Idiopathic Pulmonary Fibrosis Drug
MT Newswires Live · 04-02
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 53.45 Yuan From 51.31 Yuan, Keeps at Neutral
MT Newswires Live · 03-31
Hengrui Medicine 2024 Profit Up 47%, Revenue Rises 23%
MT Newswires Live · 03-31
DIARY-China corporate earnings week ahead
Reuters · 03-28
Chinese Shares Rise Despite Dip in Industrial Profit; Zhejiang China Commodities City Jumps 7%
MT Newswires Live · 03-27
Hengrui Medicine's Subsidiaries Get Nod to Test Three Drugs; Shares Up 5%
MT Newswires Live · 03-27
Hengrui Medicine Gets Nod to Test Tumor Drug; Shares Up 4%
MT Newswires Live · 03-27
Hengrui Medicine Grants Merck Sharp & Dohme Rights to Market Cardiovascular Drug; Shares Up 4%
MT Newswires Live · 03-26
BUZZ-Jiangsu Hengrui Pharmaceuticals rises as Merck signs licensing deal up to $2 billion
Reuters · 03-26
Hengrui Medicine Strikes Licensing Deal with Merck for HRS-5346; Shares Up 3%
MT Newswires Live · 03-26
Introduction
Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售公司的主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。公司获得获中国医药质量管理协会优秀成果及一等成果奖；公司参与编撰的江苏省地方标准《DB32/T4556-2023药品生产检验结果超标调查指南》被评为2024年度江苏省科技智库优秀成果奖。
Issue price:
11.98
Invest in Global Markets with Tiger Brokers!Open App